UVA Cancer Center expands prostate cancer awareness initiative

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.

June 06, 2025

Vol.51 No.22

Drugs & Targets

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

FDA approved the oral androgen receptor inhibitor Nubeqa (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer, which is also known as metastatic hormone-sensitive prostate cancer.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

June 06, 2025

Vol.51 No.22

Clinical Trials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.

NCI Cancer Information Highlights bulletin cut due to RIFs

NCI’s Cancer Information Highlights bulletin, a section of NCI’s Weekly Digest Bulletin that informs readers of research updates related to cancer causes, prevention, screening, treatment, and coping, will no longer be published due to restructuring and reductions in force at HHS.

May 23, 2025

Vol.51 No.20

Cancer Policy

House passes Trump’s spending bill, which now moves to the Senate

The U.S. House of Representatives voted on the so-called “One Big, Beautiful Bill Act,” this week which included drastic, $715 billion cuts to Medicaid that will result in at least 8.6 million people losing health insurance coverage, including cancer patients and survivors.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

UVA Cancer Center expands prostate cancer awareness initiative

YOU MAY BE INTERESTED IN

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

NCI Cancer Information Highlights bulletin cut due to RIFs

House passes Trump’s spending bill, which now moves to the Senate

Renew today!

Subscriber content

Never miss an issue!

Login

UVA Cancer Center expands prostate cancer awareness initiative

YOU MAY BE INTERESTED IN

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

NCI Cancer Information Highlights bulletin cut due to RIFs

House passes Trump’s spending bill, which now moves to the Senate

Never miss an issue!

Login

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime